Clinical

Dataset Information

0

A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer


ABSTRACT: This is a Phase 2, open-label, 2-part, multicenter study in subjects with MSS relapsed/refractory colorectal cancer. The primary objective of Part 1 is to evaluate the safety and tolerability of escalating doses of eFT508 in combination with a fixed dose of avelumab to determine the maximum tolerated dose (MTD) of eFT508 and to select a recommended dose for Part 2. The primary objective of Part 2 is to evaluate antitumor activity of eFT508 at the recommended dose in combination with avelumab or eFT508 monotherapy. Parts 1 and 2 will also evaluate pharmacokinetics (PK) and pharmacodynamics.

DISEASE(S): Microsatellite Stable Relapsed Or Refractory Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2252459 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2017-12-20 | GSE93192 | GEO
| 2198495 | ecrin-mdr-crc
2020-05-22 | GSE150970 | GEO
2012-04-11 | E-GEOD-37180 | biostudies-arrayexpress
| PRJNA713424 | ENA
2018-02-06 | GSE110161 | GEO
2012-04-12 | GSE37180 | GEO
| 2538194 | ecrin-mdr-crc
2023-09-14 | GSE229014 | GEO
2023-07-24 | GSE237965 | GEO